anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Sitagliptin
Trial phase: Phase 4
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: 100mg pill, PO administered once daily.

sitagliptin: 100 mg pill, administered once/day orally
Eligibility criteria:
Inclusion Criteria:

Adult age 21-70 years of age.
Diagnosis of type 2 diabetes by a physician as defined by the American Diabetes Association standard criteria: 1) Fasting Plasma glucose at or above 126 mg/dL 2) a two-hour value in an oral glucose tolerance test at or above 200 mg/dL, or 3) a random plasma glucose concentration 200 mg/dL in the presence of symptoms, or 4) glycosylated hemoglobin greater than or equal to 6.5%.
On stable metformin therapy for at least 6 weeks prior to enrollment.
Glycosylated Hemoglobin ≥6.2% and ≤ 9.5%.

Exclusion Criteria:

History of stroke, peripheral arterial disease, or coronary artery disease (as defined by the presence of at least one coronary stenosis ≥ 50% on angiography or by confirmed history of myocardial infarction by standard criteria.)
Evidence of other evident major illness including chronic renal insufficiency (creatinine clearance less than 60 mL/min),chronic liver disease (AST or ALT greater than 2.5 x normal), or cancer currently undergoing systemic therapy or had systemic therapy for cancer within 1 year of enrollment.
Pregnancy as determined by urinary beta-HCG test
Illicit drug use (heroin, cocaine etc) in the past 1 year.
Alcohol abuse, defined as the equivalent of 14 beers/week for a man or 7 beers/week for a woman
History of allergy to DPP-4 inhibitors at the time of screening/enrollment
Prior history of pancreatitis
Patients currently on insulin or sulfonylurea therapy.

Patients currently on digoxin.

-
Intervention: BranchAmin
Trial phase: Not Applicable
SMILES: CC(C)C(N)C(=O)O.CC(C)CC(N)C(=O)O.CCC(C)C(N)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 83
Group description: Receive 1-2 gm/kg/day amino acids at birth and advanced by 0.5 gm/kg/day for goal of 4 gm/kg/day

Amino acids
Eligibility criteria:
Inclusion Criteria:

birth weight 400 to 1250 grams
24 0/7 to 30 6/7 weeks gestational age

Exclusion Criteria:

chromosomal, structural, metabolic, endocrine, or renal abnormalities that could affect growth
infants >18 hours of age
infants in extremis who are unlikely to survive past 72 hours
Intervention: BranchAmin
Trial phase: Not Applicable
SMILES: CC(C)C(N)C(=O)O.CC(C)CC(N)C(=O)O.CCC(C)C(N)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 85
Group description: Receive 3-4 gm/kg/day amino acids at birth and advanced to goal of 4 gm/kg/day as soon as possible after birth

Amino acids
Eligibility criteria:
Inclusion Criteria:

birth weight 400 to 1250 grams
24 0/7 to 30 6/7 weeks gestational age

Exclusion Criteria:

chromosomal, structural, metabolic, endocrine, or renal abnormalities that could affect growth
infants >18 hours of age
infants in extremis who are unlikely to survive past 72 hours
Intervention: Ibudilast
Trial phase: Phase 2
ATC code: R03DC04
SMILES: CC(C)C(=O)c1c(C(C)C)nn2ccccc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: Ibudilast 50 mg twice daily

Ibudilast
Eligibility criteria:
Inclusion Criteria:

18 years of age or older;
meet DSM-IV-TR criteria for MA dependence (SCID verified);
a MA-positive urine drug screen at one or more visit during the two week lead-in period;
seeking treatment for MA problems;
willing and able to comply with study procedures;
provide written informed consent;
English speaking
reside within 35 miles of the clinical research site; and
if female of childbearing potential, not pregnant or lactating and willing to use a medically reliable method of birth control during the trial (e.g., birth control pills, Depo-Provera, and/or condoms with spermicide).

Exclusion Criteria:

a medical condition that, in the study physician's judgment, may interfere with safe study participation (e.g., active TB; unstable cardiac, renal, or liver disease; uncontrolled hypertension; unstable diabetes);
CD4 count < 50 cells/mm3 (suggestive of advanced HIV infection)
AST, ALT, or GGT > 3 times upper normal limit;
A corrected QT of > 450 msecs in men or > 460 msec in women on at least two ECGs during the baseline period, or clinical risk factors for Torsades de Pointes (e.g. (e.g., heart failure, hypokalemia, family history of Long QT Syndrome), or requiring ongoing treatment with concomitant medication(s) with established risk of Torsades de Pointes (e.g. Amiodarone, Arsenic trioxide, Astemizole, Bepridil, Chloroquine, Chlorpromazine, Cisapride, Citalopram, Clarithromycin, Disopyramide, Dofetilide, Domperidone, Droperidol, Erythromycin, Flecainide, Halofantrine, Haloperidol, Ibutilide, Levomethadyl, Mesoridazine, Methadone, Moxifloxacin, Pentamidine, Pimozide, Probucol, Procainamide, Quinidine, Sotalol, Sparfloxacin, Terfenadine, Thioridazine, Vandetanib);
current ongoing treatment with psychotropic medications (e.g., antidepressants, antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics);
a neurological disorder (e.g., organic brain disease, dementia) or a medical condition which would make study agent compliance difficult or which would compromise informed consent;
a major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar disorder) as assessed by the SCID;
attempted suicide in the past 3 years and/or serious suicidal intention or plan in the past year as assessed by the C-SSRS;
currently on prescription medication that is contraindicated for use with IBUD including alpha or beta agonists, theophylline, or other sympathomimetics;
current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by DSM-IV-TR;
alcohol dependence within the past year;
greater than one urine specimens during the lead-in with a riboflavin concentration of < 900 ng/ml as assessed via UV fluorescence;
a history of sensitivity to IBUD; or
any other circumstances that, in the opinion of the investigators, would compromise participant safety;
current participation in another clinical trial.
Intervention: Cipargamin
Trial phase: Phase 2
SMILES: C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Cohort 1 6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
Eligibility criteria:
Inclusion Criteria:

Male and female patients aged 20 to 60 years
Presence of mono-infection of P. falciparum
Weight between 40 kg to 90 kg

Exclusion Criteria:

Patients with signs and symptoms of severe/complicated malaria
Mixed Plasmodium infection
Presence of other serious or chronic clinical condition requiring hospitalization.
Severe malnutrition
Significant chronic medical conditions which in the opinion of the investigator preclude enrollment into the study
Intervention: Bepotastine besilate
Trial phase: Phase 3
SMILES: O=C(O)CCCN1CCC(OC(c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 240
Group description: TAU-284 10mg twice daily for 2 weeks
Eligibility criteria:
Inclusion Criteria:

Patients aged between 7 and 15 years
Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria
Patients with a mean rhinorrhea score and a mean sneezing score of at least 2 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc.

Exclusion Criteria:

Patients with vasomotor rhinitis or eosinophilic rhinitis
Patients who have concurrent nasal disease that may affect the efficacy of TAU-284
Patients with a history of any of the nasal surgical procedures
Patients who have a positive result for pollen antigens which are dispersed during the study period
Patients who have a positive result for dog dander or cat dander antigen and have a chance to touch dogs or cats.
Patients with current or previous history of drug allergy
Patients who concurrently have renal function abnormalities that may cause safety problems etc.
Intervention: Lanreotide
Trial phase: Phase 4
ATC code: H01CB03
SMILES: CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.

lanreotide: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
Eligibility criteria:
Inclusion Criteria:

age 18 - 75
elevated serum Insulin-like growth factor-1 (IGF-1) level above age- and sex-based normal values and failure of growth hormone(GH) suppression to < 1.0 ng/ml after a 75 gm oral glucose tolerance test (OGTT) American Association of Clinical Endocrinolgists (AACE) Acromegaly Clinical Guidelines 2004
visible pituitary adenoma (microadenoma or macroadenoma) on high quality pituitary MRI without and with gadolinium
prior treatments for acromegaly with surgery, somatostatin analogs or pegvisomant are acceptable if these therapies have been discontinued for at least 3 months prior to study entry

Exclusion Criteria:

Age < 18 or > 75 years
acromegalic patients currently on a lanreotide or octreotide preparation or on pegvisomant
patients who have received prior radiotherapy or radiosurgery
patients with adenoma-related visual acuity or visual field deficit from optic nerve and/or chiasm compression or severe optic nerve/chiasm compression in the setting of normal visual fields and acuity
patients with pituitary apoplexy defined as recent tumor hemorrhage and/or infarction on MRI with associated symptoms of new onset visual loss, diplopia and/or adrenal insufficiency
Intervention: Clonidine
Trial phase: Phase 1 | Phase 2
ATC code: C02AC01 | C02LC01 | C02LC51 | N02CX02 | S01EA04
SMILES: Clc1cccc(Cl)c1NC1=NCCN1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 13
Group description: Infants in this group will receive Intravenous clonidine at 1µg/kg/dose either every 6 or 8 hrs from the start of cooling to the end of re-warming

Clonidine (Duraclon®): Clonidine at dosing intervals of 4, 6, 8, 12, 18 or 24 hours.

If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.

10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration
20% drop in HR from the infant's baseline, sustained for ≥30 min after administration
HR ≤70/min, sustained for ≥30 min after administration
Eligibility criteria:
Inclusion Criteria:

Infants ≥35 0/7 weeks gestation with the diagnosis of HIE who are being treated with therapeutic hypothermia, who have indwelling arterial lines
Informed parental consent

Exclusion Criteria:

Infants who are considered moribund and the clinical team is considering withdrawal of support
Infants who need > 20 µg/kg/min of dopamine or the addition of epinephrine or dobutamine to maintain a mean arterial pressure (MAP) ≥ 45 mmHg, or milrinone for cardiovascular support
Baseline heart rate (HR) <80 bpm during hypothermia
Infants suspected of major chromosomal anomalies, except trisomy 21
Infants with major cardiovascular anomalies
Infants with severe persistent pulmonary hypertension of the newborn who are enrolled and who then need Extracorporal Membrane Oxygenation (ECMO) will be withdrawn from the study
Intervention: Integrilin
Trial phase: Phase 4
ATC code: B01AC16
SMILES: NC(=O)C1CSSCCC(=O)NC(CCCCN=C(N)N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)N2CCCC2C(=O)N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 72
Group description: Patients were given a bolus of eptifibatide (Integrillin; 180µg/kg of body weight) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg PO daily until the day of the procedure) and enoxaparin (1mg/kg SC - with the last dose 12 hours before surgery).
Eligibility criteria:
Inclusion Criteria:

Subjects must have a typical anginal pain lasting at least 20 min., but no longer than 24h.
ECG confirming ischaemia
ST segment depression >= 1,0 mm in at least 2 leads, or,
negative T waves >= 2,0 mm in at least 2 leads.
Positive troponin I (TnI).
Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent and/or parent or legal guardian must have signed a written informed consent.
Subjects must be ≥ 21 year of age, of either sex and any race.
Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD - intrauterine device, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
Subjects must be free of any clinically significant disease that would interfere with study evaluations (see exclusion criteria).
Subjects must understand and be able to adhere to the dosing and visit schedules, and agree to record concomitant medications and adverse events.

Exclusion Criteria:

Women who are pregnant or nursing.
Subjects who have not observed the designated washout periods for any of the prohibited medications.
Subjects who have used any investigational product within 30 days prior to enrollment.
Subjects who have the following clinical conditions are excluded:

Patients with:

Angina lasting longer than 24h.
ST segment elevation - Pardy wave
age over 75 years
history of revascularization procedure during last 6 months (PTCA, CABG)
chronic heart failure (NYHA III or IV) during pre-hospitalization period
history of bleeding from gastrointestinal tract or genitourinary system during last 30 days
history of intracranial lesions or stroke
history of major surgery or trauma during last 6 weeks
history of hemorrhagic diathesis
thrombocytopenia < 100 000/mm3
anticoagulant therapy with INR>2,0
significant hepatic failure
significant renal failure with serum creatinine>2,0 mg%
elevated blood pressure: SBP>200mmHg and/or DBP>110mmHg despite the antihypertensive treatment
allergy to drugs or any therapeutic agent
Intervention: Brimonidine Tartrate
Trial phase: Phase 2
SMILES: Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of ocular hypertension or glaucoma
Requires intraocular pressure (IOP)-lowering therapy

Exclusion Criteria:

Cataract surgery in one eye
Ocular laser or intraocular surgery within 6 months
Refractive surgery in either eye
Anticipated use of contact lenses during the study
Expected use of artificial tears during the study
Intervention: Ticagrelor
Trial phase: Phase 4
ATC code: B01AC24
SMILES: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Patients received a loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor was given to patients after the blood sample had been obtained 24 hours after the first dose. Thereafter, the patients took 90mg of ticagrelor orally bd. The total study period was 6 weeks.
Eligibility criteria:
Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures
2. Female or male aged at least 18 years
3. Females of child-bearing potential must have a negative urine pregnancy test at enrolment and be willing to use reliable contraception
4. Index event of non-ST or ST segment elevation ACS.

Exclusion Criteria:

1.Contraindication or other reason that clopidogrel or ticagrelor should not be administered (eg, hypersensitivity, active bleeding, moderate or severe liver disease, history of previous intracranial bleed, GI bleed within the past 6 months, major surgery within 30 days)
2. Oral anticoagulation therapy or GP IIb/IIIa receptor antagonists therapy within 30 days prior to randomisation or cannot be stopped
3. Ticagrelor or clopidogrel or other P2Y12 inhibitors within 14 days prior to randomisation
4. Requires dialysis
5. Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) and prostacyclins (PGI2) therapy that cannot be stopped
Intervention: Clopidogrel
Trial phase: Phase 4
ATC code: B01AC04
SMILES: [H][C@@](C(=O)OC)(c1ccccc1Cl)N1CCc2sccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: Patients received a loading dose of 600mg clopidogrel tablets (eight 75mg tablets) taken orally. The second dose of clopidogrel had been given to patients after the blood sample had been obtained 24 hours after the first dose. Thereafter, the patients took 75mg of clopidogrel orally od. The total study period was 6 weeks.
Eligibility criteria:
Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures
2. Female or male aged at least 18 years
3. Females of child-bearing potential must have a negative urine pregnancy test at enrolment and be willing to use reliable contraception
4. Index event of non-ST or ST segment elevation ACS.

Exclusion Criteria:

1.Contraindication or other reason that clopidogrel or ticagrelor should not be administered (eg, hypersensitivity, active bleeding, moderate or severe liver disease, history of previous intracranial bleed, GI bleed within the past 6 months, major surgery within 30 days)
2. Oral anticoagulation therapy or GP IIb/IIIa receptor antagonists therapy within 30 days prior to randomisation or cannot be stopped
3. Ticagrelor or clopidogrel or other P2Y12 inhibitors within 14 days prior to randomisation
4. Requires dialysis
5. Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) and prostacyclins (PGI2) therapy that cannot be stopped
Intervention: Caprylic acid
Trial phase: Phase 1 | Phase 2
SMILES: CCCCCCCC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Study phase 1 or 2, when participants were randomized to the 3-week intervention phase in which octanoic acid (the active drug) was taken once a day for 3 weeks.
Eligibility criteria:
Inclusion Criteria:

Participants have a diagnosis of essential voice tremor and show signs of tremor during the endoscopy examination (when pictures of the voice box are obtained)during screening appointment
Participants show measurable voice tremor from recordings of the voice during screening appointment

Exclusion Criteria:

Participants have a diagnosis or show signs of Parkinson's Disease or another non-essential tremor movement disorder
Participants have a diagnosis or show signs of spasmodic dysphonia (a different neurological voice disorder)
Participants have a diagnosis of a severe, non-stable medical condition, such as kidney or liver failure, severe heart disease, severe lung disease, severe metabolic disease, uncontrolled hyperthyroidism, or other life-threatening disease such as active cancer
Participants have a diagnosis of diabetes mellitus
Participants are unable to suspend/stop a medication that they are currently taking for tremor or voice disorder for 12 weeks to complete this study
Participants have a dependence on alcohol or allergy to alcohol
Participants are pregnant or lactating
Participants have an allergy to soy
Participants have Irritable Bowel Syndrome
Intervention: Ethanol
Trial phase: Phase 1
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 10
Group description: 74% Ethanol lock will begin within 24 hours of urinary catheter placement. Lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After 1 hour dwell time, the clamp will be removed and catheter will be flushed out by the patient's own urine output.
Eligibility criteria:
Inclusion Criteria:

Age: 6 months - 17 years
Urinary catheter placed at Children's Healthcare of Atlanta
Anticipated urinary catheter need for > 48 hours
Parent or legal guardian (or patient when applicable) consent for enrollment.

Exclusion Criteria:

18 yo or older.
Urosepsis at time of study enrollment
Known bladder or genitourinary abnormalities
Chronic bladder drainage regimen
Urologic surgeries (as part of the current admission)
Medical urgency preventing timely administration of the consenting process, or any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating.
Anuria or oliguria (<0.5 cc/kg/hr averaged over the previous 12 hours)
Other technical considerations that would prevent the timely acquisition of sufficient samples such as (but not limited to) absence of a study team member.
Parent or legal guardian (or patient when applicable) refuses to sign informed consent.
Intervention: Cabozantinib
Trial phase: Phase 3
ATC code: L01EX07 | L01XE26
SMILES: COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 331
Group description: Cabozantinib (XL184) 60 mg tablet once daily.

Cabozantinib tablets
Eligibility criteria:
Select Inclusion Criteria:

Documented histological or cytological diagnosis of renal cell cancer with a clear-cell component.
Measurable disease as determined by the investigator.
Must have received at least one VEGFR-targeting TKI (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib).
Recovery from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
Adequate organ and marrow function.
Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.
Female subjects of childbearing potential must not be pregnant at screening.

Select Exclusion Criteria:

Prior treatment with everolimus, or any other specific or selective TORC1/PI3K/AKT inhibitor (eg, temsirolimus), or cabozantinib.
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization.
Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before randomization.
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Systemic treatment with radionuclides within 6 weeks before randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.
Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors.
Chronic treatment with corticosteroids or other immunosuppressive agents.
Serious illness other than cancer.
Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before randomization and from minor surgery at least 10 days before randomization.
Pregnant or lactating females.
Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low grade tumors.